Shares of AstraZeneca Pharma India, an integrated biopharmaceutical company, surged over 10% after the company launched Fasenra in India on Apr. 20, 2021.

Benralizumab (Fasenra) is indicated as an add-on maintenance treatment for severe asthma with an eosinophilic phenotype in adult patients.

Shares of Astrazeneca Pharma India  are trading at Rs 4,313.15, up Rs 407.45, or 10.43% at the Bombay Stock Exchange (BSE) on Thursday at 3:13 p.m.

The scrip has touched an intra-day high of Rs 4,499 and low of Rs 4,061.80. The total volume of shares traded at the BSE is 147,743.

In the earlier session, the shares gained 8.77%, or Rs 314.95, at Rs 3,905.70.

Currently, the stock is trading down  13.22% from its 52-week high of Rs 4,970  and above 69.81% over the 52-week low of Rs 2,540.